<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The aim of this investigation was to develop a mathematical model of mean age, mean <z:chebi fb="107" ids="27563">arsenic</z:chebi> dietary dose, and age-specific prevalence rate for endemic <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:chebi fb="107" ids="27563">arsenic</z:chebi> poisoning </plain></SENT>
<SENT sid="1" pm="."><plain>Data on mean age (years), mean <z:chebi fb="107" ids="27563">arsenic</z:chebi> dietary dose (mg/kg body weight/day), and age-specific prevalence rate per 100,000 population for endemic <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:chebi fb="107" ids="27563">arsenic</z:chebi> poisoning in Antofagasta Commune, northern Chile, for the 1968-1971 period, were collected </plain></SENT>
<SENT sid="2" pm="."><plain>Endemic <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:chebi fb="107" ids="27563">arsenic</z:chebi> poisoning means here <z:hpo ids='HP_0011010'>chronic</z:hpo> arsenical <z:e sem="disease" ids="C0037274" disease_type="Disease or Syndrome" abbrv="">dermatosis</z:e> associated with marked or <z:e sem="disease" ids="C0264097" disease_type="Disease or Syndrome" abbrv="">sever</z:e> symptoms (or signs) of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:chebi fb="107" ids="27563">arsenic</z:chebi> poisoning (<z:hpo ids='HP_0011010'>chronic</z:hpo> diarrhoea, hepatic cirrohsis, <z:hpo ids='HP_0004469'>chronic bronchitis</z:hpo>, <z:hpo ids='HP_0002110'>bronchiectasis</z:hpo>, recurrent broncho-<z:hpo ids='HP_0002090'>pneumonia</z:hpo>, <z:hpo ids='HP_0001640'>cardiomegaly</z:hpo>, systemic <z:hpo ids='HP_0005315'>occlusive arterial disease</z:hpo>, <z:hpo ids='HP_0005305'>cerebral thrombosis</z:hpo>, etc.) There was a strong positive correlation between age-specific prevalence rate per 100,000 population and mean <z:chebi fb="107" ids="27563">arsenic</z:chebi> dose (r = + 0.9593) and a negative correlation between prevalence rate and mean age (r = 0.8789) </plain></SENT>
<SENT sid="3" pm="."><plain>These findings show that the prevalence rate declines with the advancing age and increases with the increase of <z:chebi fb="107" ids="27563">arsenic</z:chebi> dose </plain></SENT>
<SENT sid="4" pm="."><plain>A multiple linear regression model E(y) = alpha + beta X1 + gamma X2, where y represents the age-specific prevalence rate per 100,000 population, X1 the mean <z:chebi fb="107" ids="27563">arsenic</z:chebi> dose, and X2 the mean age, was fitted to the data </plain></SENT>
<SENT sid="5" pm="."><plain>The estimates of the parameters (alpha, beta, and gamma) were obtained by minimizing the residual sum of squares sigma(y - alpha - beta X1 - gamma X2)2 </plain></SENT>
<SENT sid="6" pm="."><plain>The following multiple linear regression equation was obtained: Y = 202.161 + 8452.455 X1 - 2.394 X2 </plain></SENT>
<SENT sid="7" pm="."><plain>Of the total variability in the prevalence rate, 96.22 per cent was accounted for by the multiple regression </plain></SENT>
</text></document>